drugset / Trial / NCT06066840
Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement
Phase 4
Unknown
45 enrolled
The First Affiliated Hospital of Soochow University
Affiliated Hospital of Nantong University · collabThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · collabThe First Affiliated Hospital with Nanjing Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
Acute graft-versus-host disease (aGVHD) is the most common life-threatening complication of allogeneic hematopoietic stem cell transplantation. The investigators try to observe the efficacy and safety of application of vedolizumab, anti-CD25 monoclonal antibody and rapid reduction of glucocorticoids in the treatment of grade 3-4 steroid-refractory aGVHD(SR-aGVHD) with lower gastrointestinal involvement.
Timeline
- Start
- 2022-08-01
- Primary completion
- 2025-07-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Basiliximab | Monoclonal antibody | 20 mg | — |
| Subject | Vedolizumab | Monoclonal antibody | 300 mg | — |
Indications
No indication recorded.